<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03071328</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00078508</org_study_id>
    <nct_id>NCT03071328</nct_id>
  </id_info>
  <brief_title>INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers</brief_title>
  <official_title>INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to plan for future clinical trials in patients with metastatic
      urological cancers. Diluted iodinated contrast will be injected intra-tumorally under CT
      fluoroscopy guidance into bone, lymph node, soft tissue and liver metastases in subjects with
      metastatic prostate cancer, urothelial carcinoma, or renal cell carcinoma. Pre- and
      post-injection CT images will be obtained to determine the injection parameters needed for
      optimal distribution throughout metastases of a given size. A biopsy of the metastatic site
      will also be obtained to validate expression of the receptor CD155.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study deemed non-essential under COVID pandemic
  </why_stopped>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of iodinated contrast enhancement within the metastasis on post-injection CT</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of iodinated contrast enhancement within the metastasis on post-injection CT</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of tumor CD155 membrane expression in metastatic bone, liver, soft tissue or lymph node specimens.</measure>
    <time_frame>Day 1</time_frame>
    <description>IHC will be used to assess tumor CD155 membrane expression in metastatic bone, liver, soft tissue, or lymph node specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated percentage of tumor CD155 membrane expression in metastatic bone, liver, soft tissue, or lymph node specimens.</measure>
    <time_frame>Day 1</time_frame>
    <description>IHC will be used to assess tumor CD155 membrane expression in metastatic bone, liver, soft tissue, or lymph node specimens.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer (mCRPC)</condition>
  <condition>Metastatic Urothelial Carcinoma</condition>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Bone metastatic site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver metastatic site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymph node metastatic site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Soft tissue metastatic site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isovue-M 200</intervention_name>
    <description>Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.</description>
    <arm_group_label>Bone metastatic site</arm_group_label>
    <arm_group_label>Liver metastatic site</arm_group_label>
    <arm_group_label>Lymph node metastatic site</arm_group_label>
    <arm_group_label>Soft tissue metastatic site</arm_group_label>
    <other_name>iodinated contrast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed diagnosis of adenocarcinoma of the prostate, renal cell
             carcinoma or urothelial carcinoma. Small cell or neuroendocrine tumors of the prostate
             are also permitted.

          2. Radiographic evidence of at least one bone, lymph node, soft tissue, or liver
             metastasis, that is amenable to iodinated contrast injection, as judged by the study
             radiologist

          3. Adequate laboratory values:

               1. Platelets ≥ 100,000

               2. INR ≤ 1.3

          4. Age &gt; 18 years.

          5. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. History of intercurrent or past medical or psychiatric illness that would make
             participation in a research biopsy protocol difficult or not feasible at the
             discretion of the principal investigator or co-investigator(s).

          2. Cr &gt;2.0

          3. History of iodinated contrast allergy

          4. For patients undergoing research only biopsy: Requirement for anticoagulation with
             heparin, low molecular weight heparin, clopidogrel, rivaroxaban, dabigatran, apixaban,
             warfarin, Aggrenox, fondaparux, ticagrelor, etc (aspirin and other NSAIDs are ok but
             should be held prior to biopsy in accordance with institutional standard of care)

          5. Any other contraindication to CT with iodinated contrast, as CT with contrast will be
             used in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Megan McNamara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2017</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

